Objective
to compare OAC alone versus OAC + single antiplatelet therapy (APT)
Study
prospective, multicentre, open-label, noninferiority trial
Population
patients with atrial fibrillation beyond 1-year after stenting
Endpoints
composite of all-cause death, myocardial infarction, stroke, or systemic embolism
Conclusion
non-inferiority of OAC alone compared to OAC + single antiplatelet therapy was not established. Due to premature termination of enrolment the trial was underpowered and non-conclusive
Matsumura-Nakano et al. Circulation. 2019;139:604-16
